Dr. Reddys Laboratories Limited

FORTHCOMING DEADLINE: J&W Announces Class Action Suit against Dr. Reddys Laboratories Limited; Investors Encouraged to Contact Firm

SAN DIEGO- PRNewswire —September 2, 2017

Johnson & Weaver, LLP reminds investors that a class action case was filed against Dr. Reddys Laboratories Limited (NYSE: RDY) (“Dr. Reddys”) for purchasers of the stock between June 17, 2015 and August 10, 2017, inclusive (the “Class Period”).

The complaint alleges that during the Class Period, defendants made false and misleading statements and failed to disclose that; (1) Dr. Reddy’s lacked an effective corporate quality system; and (2) as a result, defendants’ public statements were materially false and misleading at all relevant times.

On August 10, 2017, Dr. Reddy’s disclosed that the Regulatory of Germany did not renew the good manufacturing practices compliance certificate of a formulations manufacturing unit of its German subsidiary Betapharm Arzneimittel, located in Hyderabad, India, following a recent inspection of the plant.

If you purchased shares during the Class Period and suffered a loss in Teva, you have until October 24, 2017 to request that the Court appoint you as lead plaintiff.

If you are interested in learning more about your legal rights and remedies or becoming a lead plaintiff in this case, please contact analyst Jim Baker (jimb@johnsonandweaver.com) at 619-814-4471. If you email, please include your phone number.

About Johnson & Weaver, LLP:
Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.

Johnson & Weaver, LLP
Jim Baker, 619-814-4471